ISBN 10: 1287212565 / ISBN 13: 9781287212560
Gebraucht / Anzahl: 0
Bei weiteren Verkäufern erhältlich
Alle  Exemplare dieses Buches anzeigen

Über dieses Buch

Leider ist dieses Exemplar nicht mehr verfügbar. Wir haben Ihnen weitere Exemplare dieses Titels unten aufgelistet.

Beschreibung:

This Book is in Good Condition. Clean Copy With Light Amount of Wear. 100% Guaranteed. Buchnummer des Verkäufers

Über diesen Titel:

Inhaltsangabe: Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and Drug Administration (FDA). Recent scientific advances have raised expectations that an increasing number of new and innovative drugs would soon be developed to more effectively prevent, treat, and cure serious illnesses. However, industry analysts and the FDA have reported that new drug development, and in particular, development of new molecular entities (NMEs)--potentially innovative drugs containing ingredients that have never been marketed in the United States--has become stagnant. GAO was asked to provide information on (1) trends in the pharmaceutical industry's reported research and development expenses as well as trends in the number of NDAs submitted to, and approved by, FDA; and (2) experts' views on factors accounting for these trends and their suggestions for expediting and enhancing drug development. GAO analyzed data from FDA on all 1,264 NDAs submitted to the agency from 1993 through 2004. GAO also convened a panel of experts and interviewed other drug development experts and analysts to identify factors affecting, and suggestions for enhancing, drug development.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Bibliografische Details

Zustand: Used

Beste Suchergebnisse bei AbeBooks

1.

U.S. Government Accountability Office (G
Verlag: BiblioGov (2016)
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Paperback Anzahl: 1
Print-on-Demand
Anbieter
Ria Christie Collections
(Uxbridge, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung BiblioGov, 2016. Paperback. Buchzustand: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Buchnummer des Verkäufers ria9781287212560_lsuk

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 16,32
Währung umrechnen

In den Warenkorb

Versand: EUR 4,47
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

2.

Verlag: Bibliogov, United States (2013)
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Bibliogov, United States, 2013. Paperback. Buchzustand: New. 246 x 189 mm. Language: English . Brand New Book ***** Print on Demand *****.Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and Drug Administration (FDA). Recent scientific advances have raised expectations that an increasing number of new and innovative drugs would soon be developed to more effectively prevent, treat, and cure serious illnesses. However, industry analysts and the FDA have reported that new drug development, and in particular, development of new molecular entities (NMEs)--potentially innovative drugs containing ingredients that have never been marketed in the United States--has become stagnant. GAO was asked to provide information on (1) trends in the pharmaceutical industry s reported research and development expenses as well as trends in the number of NDAs submitted to, and approved by, FDA; and (2) experts views on factors accounting for these trends and their suggestions for expediting and enhancing drug development. GAO analyzed data from FDA on all 1,264 NDAs submitted to the agency from 1993 through 2004. GAO also convened a panel of experts and interviewed other drug development experts and analysts to identify factors affecting, and suggestions for enhancing, drug development. Buchnummer des Verkäufers AAV9781287212560

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 18,67
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

3.

Verlag: Bibliogov, United States (2013)
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository US
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Bibliogov, United States, 2013. Paperback. Buchzustand: New. 246 x 189 mm. Language: English . Brand New Book ***** Print on Demand *****. Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and Drug Administration (FDA). Recent scientific advances have raised expectations that an increasing number of new and innovative drugs would soon be developed to more effectively prevent, treat, and cure serious illnesses. However, industry analysts and the FDA have reported that new drug development, and in particular, development of new molecular entities (NMEs)--potentially innovative drugs containing ingredients that have never been marketed in the United States--has become stagnant. GAO was asked to provide information on (1) trends in the pharmaceutical industry s reported research and development expenses as well as trends in the number of NDAs submitted to, and approved by, FDA; and (2) experts views on factors accounting for these trends and their suggestions for expediting and enhancing drug development. GAO analyzed data from FDA on all 1,264 NDAs submitted to the agency from 1993 through 2004. GAO also convened a panel of experts and interviewed other drug development experts and analysts to identify factors affecting, and suggestions for enhancing, drug development. Buchnummer des Verkäufers AAV9781287212560

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 20,68
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach USA
Versandziele, Kosten & Dauer

4.

ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Anzahl: > 20
Print-on-Demand
Anbieter
BWB
(Valley Stream, NY, USA)
Bewertung
[?]

Buchbeschreibung Buchzustand: New. This item is Print on Demand - Depending on your location, this item may ship from the US or UK. Buchnummer des Verkäufers POD_9781287212560

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 20,69
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer

5.

Verlag: BiblioGov
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Paperback Anzahl: 20
Print-on-Demand
Anbieter
BuySomeBooks
(Las Vegas, NV, USA)
Bewertung
[?]

Buchbeschreibung BiblioGov. Paperback. Buchzustand: New. This item is printed on demand. Paperback. 56 pages. Dimensions: 9.7in. x 7.4in. x 0.1in.Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and Drug Administration (FDA). Recent scientific advances have raised expectations that an increasing number of new and innovative drugs would soon be developed to more effectively prevent, treat, and cure serious illnesses. However, industry analysts and the FDA have reported that new drug development, and in particular, development of new molecular entities (NMEs)--potentially innovative drugs containing ingredients that have never been marketed in the United States--has become stagnant. GAO was asked to provide information on (1) trends in the pharmaceutical industrys reported research and development expenses as well as trends in the number of NDAs submitted to, and approved by, FDA; and (2) experts views on factors accounting for these trends and their suggestions for expediting and enhancing drug development. GAO analyzed data from FDA on all 1, 264 NDAs submitted to the agency from 1993 through 2004. GAO also convened a panel of experts and interviewed other drug development experts and analysts to identify factors affecting, and suggestions for enhancing, drug development. This item ships from La Vergne,TN. Paperback. Buchnummer des Verkäufers 9781287212560

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 19,60
Währung umrechnen

In den Warenkorb

Versand: EUR 3,52
Innerhalb USA
Versandziele, Kosten & Dauer

6.

Verlag: BiblioGov (2013)
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Paperback Anzahl: 1
Anbieter
Irish Booksellers
(Rumford, ME, USA)
Bewertung
[?]

Buchbeschreibung BiblioGov, 2013. Paperback. Buchzustand: New. book. Buchnummer des Verkäufers 1287212565

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 27,83
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer

7.

Verlag: BiblioGov
ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu PAPERBACK Anzahl: > 20
Anbieter
Russell Books
(Victoria, BC, Kanada)
Bewertung
[?]

Buchbeschreibung BiblioGov. PAPERBACK. Buchzustand: New. 1287212565 Special order direct from the distributor. Buchnummer des Verkäufers ING9781287212560

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 19,54
Währung umrechnen

In den Warenkorb

Versand: EUR 6,23
Von Kanada nach USA
Versandziele, Kosten & Dauer

8.

ISBN 10: 1287212565 ISBN 13: 9781287212560
Neu Anzahl: 1
Anbieter
Castle Rock
(Pittsford, NY, USA)
Bewertung
[?]

Buchbeschreibung Buchzustand: Brand New. Book Condition: Brand New. Buchnummer des Verkäufers 97812872125601.0

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 37,36
Währung umrechnen

In den Warenkorb

Versand: EUR 3,55
Innerhalb USA
Versandziele, Kosten & Dauer

9.

BiblioGov
Verlag: BiblioGov (2013)
ISBN 10: 1287212565 ISBN 13: 9781287212560
Gebraucht Paperback Anzahl: 1
Anbieter
Books Express
(Portsmouth, NH, USA)
Bewertung
[?]

Buchbeschreibung BiblioGov, 2013. Paperback. Buchzustand: Used: Good. Ships with Tracking Number! INTERNATIONAL WORLDWIDE Shipping available. May not contain Access Codes or Supplements. Buy with confidence, excellent customer service!. Buchnummer des Verkäufers 1287212565

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Gebraucht kaufen
EUR 107,30
Währung umrechnen

In den Warenkorb

Versand: Gratis
Innerhalb USA
Versandziele, Kosten & Dauer